Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 8/2017

Open Access 01-08-2017 | Review

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Authors: Franck Boccara, Ricardo Dent, Luis Ruilope, Paul Valensi

Published in: Advances in Therapy | Issue 8/2017

Login to get access

Abstract

Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. These drugs are administered subcutaneously and offer efficacious treatment options with reduced dosing frequency. Whilst patients with diabetes and diabetologists are well initiated to injectable therapies, the cardiovascular therapeutic arena has traditionally been dominated by oral agents. It is therefore important to examine the practical aspects of treating patients with these new lipid-lowering agents, to ensure they are optimally deployed in everyday clinical practice.
Literature
1.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.PubMedCrossRef
2.
Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: US prescription drug data for 2007–2008. NCHS Data Brief. 2010;42:1–8.
3.
Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24(1):9–17.PubMedCrossRef
4.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25(9):1751–62.PubMedCrossRef
5.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.PubMedCrossRef
6.
Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–87.CrossRef
7.
Jörgensen T, Johansson S, Kennerfalk A, Wallander M-A, Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35(9):1004–9.PubMedCrossRef
8.
Haider S, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007;45(12):643–53.PubMedCrossRef
9.
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–44.PubMedCrossRef
10.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.PubMedCrossRef
11.
Steinman MA, Seth Landefeld C, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.PubMedCrossRef
12.
Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864–70.PubMedCrossRef
13.
Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294(10):1240–7.PubMedCrossRef
14.
15.
Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.PubMedCrossRef
16.
Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2013;29(10):1275–86.PubMedCrossRef
17.
Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.PubMedCrossRef
18.
Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958–71.PubMedCrossRef
19.
Boswell KA, Cook CL, Burch SP, Eaddy MT, Cantrell CR. Associating medication adherence with improved outcomes: a systematic literature review. Am J Pharm Benefits. 2012;4(4):e97–108.
20.
Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836–41.PubMedCrossRef
21.
Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff. 2012;31(8):1836–46.CrossRef
22.
Stuart BC, Simoni-Wastila L, Zhao L, Lloyd JT, Doshi JA. Increased persistency in medication use by US Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care. 2009;32(4):647–9.PubMedPubMedCentralCrossRef
23.
Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskel Disord. 2007;8(1):97.CrossRef
24.
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.CrossRef
25.
Hemingway S. Medicines adherence-involving patients in decisions about prescribed medicines and supporting adherence: NICE clinical guideline 76. Mental Health Nurs (Online). 2009;29(2):10.
26.
27.
Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci. 2006;28(3):165–70.PubMedCrossRef
28.
Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;8(1):1.CrossRef
29.
Maddigan SL, Farris KB, Keating N, Wiens CA, Johnson JA. Predictors of older adults’ capacity for medication management in a self-medication program a retrospective chart review. J Aging Health. 2003;15(2):332–52.PubMedCrossRef
30.
Dilorio C, Yeager K, Shafer PO, Letz R, Henry T, Schomer DL, et al. The epilepsy medication and treatment complexity index: reliability and validity testing. J Neurosci Nurs. 2003;35(3):155–62.CrossRef
31.
Elliott RA, O’Callaghan CJ. Impact of hospitalisation on the complexity of older patients’ medication regimens and potential for regimen simplification. J Pharm Pract Res. 2011;41(1):21–5.CrossRef
32.
Martin S, Wolters PL, Calabrese SK, Toledo-Tamula MA, Wood LV, Roby G, et al. The antiretroviral regimen complexity index: a novel method of quantifying regimen complexity. J Acquir Immune Defic Syndr. 2007;45(5):535–44.PubMedCrossRef
33.
Pharmacists ASoH-S. Pharmacy practice model summit. Executive summary. Am J Health Syst Pharm. 2011;68(12):1079–85.CrossRef
34.
Boyd C, McNabney M, Brandt N. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60:1957–68.CrossRef
35.
Paquin AM, Zimmerman KM, Kostas TR, Pelletier L, Hwang A, Simone M, et al. Complexity perplexity: a systematic review to describe the measurement of medication regimen complexity. Expert Opin Drug Saf. 2013;12(6):829–40.PubMedCrossRef
36.
Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–39.PubMed
37.
Corsonello A, Pedone C, Lattanzio F, Lucchetti M, Garasto S, Carbone C, et al. Regimen complexity and medication nonadherence in elderly patients. Ther Clin Risk Manag. 2009;5:209.PubMedPubMedCentralCrossRef
38.
Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.PubMedPubMedCentralCrossRef
39.
DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521–8.PubMedCrossRef
40.
Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95(1):68–72.PubMedCrossRef
41.
Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269.PubMedPubMedCentral
42.
Pollack M, Chastek B, Williams SA, Moran J. Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. JCOM. 2010;17(6):257–65.
43.
Hughes M. Prefilled syringes: injecting the end-user’s perspec-tive. Drug Deliv Technol. 2010;10:18–23.
44.
Ridyard CH, Dawoud DM, Tuersley LV, Hughes DA. A systematic review of patients’ perspectives on the subcutaneous route of medication administration. Patient. 2016.
45.
Harris M, Joy R, Larsen G, Valyi M, Walker E, Frick LW, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS. 2006;20(5):719–23.PubMedCrossRef
46.
Boyd MA, Truman M, Hales G, Anderson J, Dwyer DE, Carr A. Short communication A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antivir Ther. 2008;13:449–53.PubMed
47.
Ahmed SF, Smith W, Blamires C. Facilitating and understanding the family’s choice of injection device for growth hormone therapy by using conjoint analysis. Arch Dis Child. 2008;93(2):110–4.PubMedCrossRef
48.
Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert R, editors. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clinic Proceedings; 2007: Elsevier.
49.
Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.PubMedPubMedCentralCrossRef
50.
Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009;11(8):529–38.PubMedCrossRef
51.
Odegard PS, Capoccia K. Medication taking and diabetes a systematic review of the literature. Diabetes Educator. 2007;33(6):1014–29.PubMedCrossRef
52.
Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94–107.PubMedPubMedCentralCrossRef
53.
Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87(2):204–10.PubMedCrossRef
54.
Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22(3):147–50.CrossRef
55.
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.PubMedCrossRef
56.
Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(5):27–34.CrossRef
57.
Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12(6):915–22.PubMedCrossRef
58.
Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care. 2012;18(3 Suppl):S43–8.PubMed
59.
Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12(S1).
60.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–47.PubMedCrossRef
61.
Brod M, Valensi P, Shaban JA, Bushnell DM, Christensen TL. Patient treatment satisfaction after switching to NovoMix(R) 30 (BIAsp 30) in the IMPROVE study: an analysis of the influence of prior and current treatment factors. Qual Life Res. 2010;19(9):1285–93.PubMedPubMedCentralCrossRef
62.
Reach G, Le Pautremat V, Gupta S. Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. Patient Prefer Adherence. 2013;7:1007–23.PubMedPubMedCentralCrossRef
63.
Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Pract. 2013;19(2):327–36.CrossRef
64.
Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(10):882–92.PubMedCrossRef
65.
66.
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–50.PubMedCrossRef
67.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.PubMedCrossRef
68.
Buse JB, Sesti G, Schmidt WE, Montanya E, Chang C-T, Xu Y, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–3.PubMedPubMedCentralCrossRef
69.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.PubMed
70.
Johnston SS, Nguyen H, Felber E, Cappell K, Nelson JK, Chu BC, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119–33.PubMedCrossRef
71.
Zhang L, Zakharyan A, Stockl KM, Harada AS, Curtis BS, Solow BK. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ. 2011;14(5):562–7.PubMedCrossRef
72.
Hauber AB, Nguyen H, Posner J, Ervin C, LaRue S, Kalsekar I, editors. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes. ISPOR 19th Annual International Meeting; 2014.
73.
Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Primary Care Diabetes. 2010;4(2):113–7.PubMedCrossRef
74.
Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314–9.PubMedPubMedCentralCrossRef
75.
Pratley R, Nauck M, Bailey T, Group L-D-S. Switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide further improves glycemic control and weight loss in patients with type 2 diabetes. Diabetes. 2011;60(suppl 1):A307–8.
76.
Montanya E, Pratley R, Nauck M, Bailey T, Garber A, Filetti S, et al. Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes. Diabetes. 2011;60(Suppl 1):A307.
77.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016.
78.
Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.PubMedCrossRef
79.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.PubMedCrossRef
80.
Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.CrossRef
81.
Nathan DM. Rosiglitazone and cardiotoxicity—weighing the evidence. N Engl J Med. 2007;357(1):64–6.PubMedCrossRef
82.
Krobot KJ, Yin DD, Alemao E, Steinhagen-Thiessen E. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil. 2005;12(1):37–45.PubMedCrossRef
83.
Antiochos P, Marques-Vidal P, Waeber G, Vollenweider P. Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study. Nutr Metab Cardiovasc Dis. 2015;25(11):1007–15.PubMedCrossRef
84.
Bongard V, Dallongeville J, Arveiler D, Ruidavets J-B, Amouyel P, Wagner A, et al. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: insights from the MONA LISA study. Arch Cardiovasc Dis. 2013;106(2):93–102.PubMedCrossRef
85.
Bruckert E, Ferrières J. Evidence supporting primary prevention of cardiovascular diseases with statins: gaps between updated clinical results and actual practice. Arch Cardiovasc Dis. 2014;107(3):188–200.PubMedCrossRef
86.
Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119(8):676–83.PubMedCrossRef
87.
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858–68.PubMedCrossRef
88.
Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8):S52–60.CrossRef
89.
Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393–403.PubMedCrossRef
90.
Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015:ehv641.
91.
Bittner V, Deng L, Rosenson RS, Taylor B, Glasser SP, Kent ST, et al. Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the medicare population 2007 to 2011. J Am Coll Cardiol. 2015;66(17):1864–72.PubMedCrossRef
92.
Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, et al. Statin underuse and low prevalence of LDL-C control among US adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108–14.PubMedPubMedCentralCrossRef
93.
Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65(3):270–7.PubMedCrossRef
94.
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164(4):208–11.PubMed
95.
Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458–62.PubMedCrossRef
96.
Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21(6):485–8.PubMed
97.
Lázaro P, Murga N, Aguilar D, Hernández-Presa MA, Investigators IS. Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study. Rev Esp Cardiol (English Edition). 2010;63(12):1428–37.
98.
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.PubMedCrossRef
99.
Krempf M, Simpson RJ, Ramey DR, Brudi P, Giezek H, Tomassini JE, et al. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis. 2015;14(1):45.PubMedPubMedCentralCrossRef
100.
Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–96.PubMedCrossRef
101.
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.PubMedPubMedCentralCrossRef
102.
Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.PubMedPubMedCentralCrossRef
103.
Goldacre B. Meta-analysis of side effects of statins shows need for trial transparency. BMJ. 2014;348:g2940.PubMedCrossRef
104.
Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients’ perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4–10.PubMedCrossRef
105.
106.
107.
Stone NJ. Reducing residual risk in secondary prevention of cardiovascular disease. Circulation. 2012;125(16):1958–60.PubMedCrossRef
108.
Pirillo A, Catapano AL. Statin intolerance: diagnosis and remedies. Curr Cardiol Rep. 2015;17(5):27.PubMedCrossRef
109.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.PubMedCrossRef
110.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.PubMedCrossRef
111.
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.PubMedCrossRef
112.
Dent R, Joshi R, Djedjos CS, Legg J, Elliott M, Geller M, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 2016;5(1):1.CrossRef
113.
Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117(1):40–7.PubMedCrossRef
114.
Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40.PubMedCrossRef
115.
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–40.PubMedCrossRef
116.
Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8.PubMedCrossRef
117.
118.
119.
Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.CrossRef
120.
Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–91.CrossRef
121.
Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74.CrossRef
122.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.PubMedCrossRef
123.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88.PubMedCrossRef
124.
Writing C, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68(1):92–125.CrossRef
125.
126.
127.
Sathiyakumar V, Martin SS, Jones S, Quinn J, Green R, Lesko A, et al. Real-world PCSK9i experience: the importance of a multidisciplinary approach. J Clin Lipidol. 2017;11(3):803.CrossRef
128.
129.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.PubMedCrossRef
130.
Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35(33):2249–59.PubMedCrossRef
131.
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–83.PubMedCrossRef
132.
Koren MJ, Djedjos C, Ma Y, Somaratne R, Bolognese M. The Osler-2 study: patients’ preferences and compliance with biweekly or monthly dosing during treatment of hypercholesterolemia with evolocumab [abstract]. J Am Coll Cardiol. 2016;67(13_S):1995.CrossRef
133.
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.PubMedCrossRef
134.
Stein EA, Koren M, Honarpour N, Kurtz C, Yang J, Wasserman S, et al. Clinical equivalence of evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies. J Am Coll Cardiol. 2015;65(10_S).
135.
136.
137.
Farnier M, Colhoun HM, Sasiela WJ, Edelberg J, Asset G, Robinson JG. Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six odyssey phase 3 clinical studies with treatment duration of 52–104 weeks [abstract]. Presented at 84th EAS Congress 2016, Austria. OT05 Workshop (Late Breaking: Clinical Science).
138.
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–40.PubMedCrossRef
Metadata
Title
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Authors
Franck Boccara
Ricardo Dent
Luis Ruilope
Paul Valensi
Publication date
01-08-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 8/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0586-8

Other articles of this Issue 8/2017

Advances in Therapy 8/2017 Go to the issue

Review

Monovision Versus Multifocality for Presbyopia: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Original Research

Health-Related Quality of Life in Individuals with Down Syndrome: Results from a Non-Interventional Longitudinal Multi-National Study

Review

Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications

Original Research

Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy

Review

Dexpanthenol: An Overview of its Contribution to Symptom Relief in Acute Rhinitis Treated with Decongestant Nasal Sprays

Original Research

Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits